For the quarter ended September 2023, Baxter International (BAX - Free Report) reported revenue of $3.71 billion, down 1.7% over the same period last year. EPS came in at $0.68, compared to $0.82 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +0.52%. The company delivered an EPS surprise of +3.03%, with the consensus EPS estimate being $0.66.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Acute Therapies- U.S. $66 million versus the three-analyst average estimate of $59.38 million. The reported number represents a year-over-year change of +24.5%.
- Sales- Acute Therapies- International: $122 million versus $112.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.2% change.
- Sales- Pharmaceuticals- U.S. $195 million versus the three-analyst average estimate of $184.52 million. The reported number represents a year-over-year change of +12.7%.
- Sales- Pharmaceuticals- International: $385 million compared to the $369.56 million average estimate based on three analysts. The reported number represents a change of +9.4% year over year.
- Sales- Advanced Surgery- U.S. $139 million versus $147.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.4% change.
- Geographic Sales- International: $1.94 billion compared to the $1.89 billion average estimate based on three analysts. The reported number represents a change of -6.2% year over year.
- Sales- Other- U.S. $12 million versus $24.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -57.1% change.
- Sales- Acute Therapies: $188 million versus the four-analyst average estimate of $172.03 million. The reported number represents a year-over-year change of +19%.
- Sales- Pharmaceuticals: $580 million versus $548.31 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
- Sales- Front Line Care: $301 million versus $307.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
- Sales- Other: $17 million compared to the $34.84 million average estimate based on four analysts. The reported number represents a change of -55.3% year over year.
- Sales- Advanced Surgery: $255 million versus the four-analyst average estimate of $260.06 million. The reported number represents a year-over-year change of +3.2%.
View all Key Company Metrics for Baxter here>>>Shares of Baxter have returned -11.3% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
For the quarter ended September 2023, Baxter International (BAX - Free Report) reported revenue of $3.71 billion, down 1.7% over the same period last year. EPS came in at $0.68, compared to $0.82 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +0.52%. The company delivered an EPS surprise of +3.03%, with the consensus EPS estimate being $0.66.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Acute Therapies- U.S. $66 million versus the three-analyst average estimate of $59.38 million. The reported number represents a year-over-year change of +24.5%.
- Sales- Acute Therapies- International: $122 million versus $112.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.2% change.
- Sales- Pharmaceuticals- U.S. $195 million versus the three-analyst average estimate of $184.52 million. The reported number represents a year-over-year change of +12.7%.
- Sales- Pharmaceuticals- International: $385 million compared to the $369.56 million average estimate based on three analysts. The reported number represents a change of +9.4% year over year.
- Sales- Advanced Surgery- U.S. $139 million versus $147.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.4% change.
- Geographic Sales- International: $1.94 billion compared to the $1.89 billion average estimate based on three analysts. The reported number represents a change of -6.2% year over year.
- Sales- Other- U.S. $12 million versus $24.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -57.1% change.
- Sales- Acute Therapies: $188 million versus the four-analyst average estimate of $172.03 million. The reported number represents a year-over-year change of +19%.
- Sales- Pharmaceuticals: $580 million versus $548.31 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
- Sales- Front Line Care: $301 million versus $307.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
- Sales- Other: $17 million compared to the $34.84 million average estimate based on four analysts. The reported number represents a change of -55.3% year over year.
- Sales- Advanced Surgery: $255 million versus the four-analyst average estimate of $260.06 million. The reported number represents a year-over-year change of +3.2%.
View all Key Company Metrics for Baxter here>>>Shares of Baxter have returned -11.3% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on BAX - FREE